Luděk Pour

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

Francesca Gay, Wilfried Roeloffzen, Meletios A. Dimopoulos, Laura Rosiñol et autres

Abstract Induction and consolidation with a quadruplet therapy of a CD38-targeting monoclonal antibody, a proteasome inhibitor, an immunomodulatory drug and dexamethasone are a standard-of-care treatment in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM) with the optimal drugs to be used …

it, nl, kr, gr, es, cz, de, no (code pays fourni par la source)

Changes in hemostasis and other disorders caused by monoclonal immunoglobulin and/or free light chains

Zdeněk Adam, Zdeněk Řehák, Marta Krejčí, Ivanna Boichuk et autres

BACKGROUND: Monoclonal immunoglobulin and/or free light chains cause diverse complications that can affect almost all tissues or organs. AIM: Monoclonal immunoglobulin can interfere with hemostasis and cause both hypercoagulation or hemorrhagic diathesis. In patients with non-malignant gammopathy and untreated multiple myeloma, thrombotic …

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO

Gurdeep Parmar, Marcelo Capra, Fernanda Salles Seguro, Vania Hungria et autres

In the Phase 2 IZALCO study, we evaluated efficacy, patient preference, safety and pharmacokinetics for isatuximab administered SC by an innovative on-body injector (OBI) or manual injection, plus carfilzomib-dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM) patients. In Part 1, isatuximab SC was …

au, br, kr, gr, cz, pt, jp, fr, us, gb (code pays fourni par la source)

Polyclonal hypergammaglobulinemia, infiltration of the salivary glands, lymphadenopathy, and kidney damage – Mikulicz’s disease, Sjögren’s syndrome, or Castleman’s disease? Case report and overview of differential diagnosis and treatment

Z. Adam, Zdeněk Fojtík, Zdeněk Řehák, Václav Kubeš et autres

BACKGROUND: Polyclonal hypergammaglobulinemia has a variety of causes, which we outline in the text. Regularly, very high concentrations of polyclonal immunoglobulins are observed in IgG4-related disease, Sjögren's syndrome, and in the idiopathic multicentric Castleman disease. OBSERVATION: We describe a patient who had …

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies

Alexandra Jungová, Martin Štork, Ivan Špıčka, Jakub Radocha et autres

cz (code pays fourni par la source)

Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data

Michal Kaščák, Prokop Vodička, S. J. Martin, Zdeněk Adam et autres

Abstract Introduction Waldenström's macroglobulinemia (WM) is a rare, indolent, IgM-producing lymphoplasmacytic lymphoma with diverse clinical outcomes. Prognostic models have evolved alongside treatment shifts from chemotherapy to chemoimmunotherapy and targeted therapies. In addition to the original International Prognostic Scoring System for WM (IPSSWM), …

cz (code pays fourni par la source)

Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Eyal Lebel, Ahmed Abdulgawad, Stéfania Bramanti, Gonzalo Martin Garate et autres

Abstract Background and Significance: Despite advances in multiple myeloma (MM) treatment, nearly all patients (pts) will relapse, highlighting the need for new drug classes to improve outcomes in RRMM. Further, with the extensive use of lenalidomide, an immunomodulatory drug (IMiD), in frontline …

il, gb, it, ar, au, fi, dk, ca, pl, es, cz, gr, de, us, se (code pays fourni par la source)

Precision medicine in hemato-oncology – treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/MEK inhibitors

Martin Štork, Jana Kotašková, Eva Ondroušková, Marek Borský et autres

BACKGROUND: Multiple myeloma (MM) with extramedullary disease (EMD) represents a subgroup with particularly poor prognosis. The application of precision medicine principles, especially targeted therapy based on the tumor's molecular profile, is a potentially effective treatment strategy. CASE: We present a case of …

Monoclonal gammopathy of clinical significance – a group name for diseases caused by monoclonal immunoglobulin and/or free light chains. A change in the approach to non-malignant gammopathies

Zdeněk Adam, Zdeněk Řehák, Marta Krejčí, Ivanna Boichuk et autres

BACKGROUND: The group of monoclonal gammopathies includes both malignant diseases, such as multiple myeloma and Waldenström's macroglobulinemia, and benign proliferations of plasma cells or lymphoplasmacytic cells with the formation of usually low concentrations of monoclonal immunoglobulin and/or free light chains. The term …

DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF TRANSPLANT- INELIGIBLE (TIE) PATIENTS IN THE PHASE 3 CEPHEUS STUDY

Thierry T.F. Facon, Sonja Zweegman, V Hungria, NJ Bahlis et autres

After reading out of the PERSEUS and CEPHEUS trials, daratumumab-based therapy + VRd is emerging as the standard of care in NDMM treatment. In CEPHEUS (NCT03652064), DVRd improved minimal residual disease negativity (MRD neg) and progression-free survival (PFS) vs VRd in patients …

fr, nl, br, ca, us, cz, es (code pays fourni par la source)

DARATUMUMAB + BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) VS VRD IN TRANSPLANT-INELIGIBLE (TIE)/TRANSPLANT-DEFERRED (TD) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 3 CEPHEUS TRIAL CYTOGENETIC SUBGROUP ANALYSIS

NJ Bahlis, S. Z. Usmani, Thierry T.F. Facon, Sonja Zweegman et autres

In CEPHEUS, DVRd significantly improved overall MRD negativity (MRD neg + ≥CR) and sustained MRD neg rates and PFS in patients (pts) with TIE/TD NDMM. In this post hoc analysis, we report outcomes in cytogenetic risk subgroups. To gain additional insight into …

ca, us, fr, nl, cz, es, br (code pays fourni par la source)

Efficacy and Safety of Isatuximab Subcutaneous (SC) Plus Carfilzomib and Dexamethasone (Isa-Kd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results of the Phase 2 Study IZALCO

Gurdeep Parmar, Marcelo Capra, Fernanda Salles Seguro, Vania Tietsche de Moraes Hungria et autres